New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:16 EDTBAX, HSPBaxter rationing supplies of nitroglycerin since January, NY Times says
The New York Times reports that Baxter (BAX) has been unable to keep up with demand for injectable nitroglycerin since Hospira (HSP) and American Regent stopped selling their products due to manufacturing problems and delays. The company has been rationing supplies off the drug since January. Reference Link
News For BAX;HSP From The Last 14 Days
Check below for free stories on BAX;HSP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
09:28 EDTHSPHospira sees FY14 gross margin 39%-40%
Subscribe for More Information
08:08 EDTBAXBaxter announces divestiture of commercial vaccines business to Pfizer for $635M
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer (PFE) for a total cash consideration of $635M, subject to certain adjustments. The sale includes the company’s commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis, an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets. Baxter continues to explore strategic options, including the potential for partnering or divesting its R&D development programs focused on influenza and Lyme disease. Subject to regulatory approvals and other customary closing conditions, the companies expect to close the transaction by the end of 2014. Baxter expects 2014 vaccines revenues to total approximately $300M and adjusted earnings of approximately 25c per diluted share, including approximately $50M of one-time milestone payments related to the ongoing government collaborations for development of influenza vaccines. Baxter expects the transaction to be modestly dilutive to fourth quarter 2014 adjusted earnings and dilutive to 2015 adjusted earnings by approximately 15c per diluted share.
08:01 EDTBAXPfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Subscribe for More Information
07:35 EDTHSPHospira sees FY14 adjusted EPS $2.30-$2.50, consensus $2.22
Raises FY14 cash flow from operations to $275M-$375M from $200M-$300M; Backs FY14 CapEx $375M-$425M; Backs FY14 depreciation and amortization to range $225M-$275M.
07:34 EDTHSPHospira reports Q2 adjusted EPS 72c, consensus 57c
Subscribe for More Information
July 29, 2014
15:53 EDTHSPNotable companies reporting before tomorrow's open
Subscribe for More Information
07:19 EDTHSPCBI to hold a conference
Subscribe for More Information
July 28, 2014
12:42 EDTHSPHospira, Danone rise following report of deal talks
Subscribe for More Information
08:12 EDTHSPHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
July 27, 2014
15:12 EDTHSP Hospira in talks to acquire Danone medical nutrition business, FT says
French consumer company Danone (DANOY) has been in negotiations to sell its medical nutrition business to Hospira (HSP) in a deal said to value the unit at $5B, says the Financial Times. The deal would also allow for U.S. based Hospira to domicile its tax base in Europe in a tax strategy known as an inversion, added the Financial Times. In prior reports, Nestle (NSRGY) and Fresenius (FMS) have also been mentioned as suitors for the Danone unit. Reference Link
July 23, 2014
10:02 EDTHSPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTHSPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTHSPHospira initiated with a Hold at Deutsche Bank
Target $53.
July 18, 2014
10:48 EDTHSPHigh option volume stocks
Subscribe for More Information
July 17, 2014
09:15 EDTBAXBaxter says 'feels good' about guidance
Subscribe for More Information
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Subscribe for More Information
07:05 EDTBAXBaxter sees Q3 EPS before special items $1.28-$1.32, consensus $1.32
The company said, "For Q3, the company expects sales growth of approximately 12%-13%, excluding the impact of foreign currency. TheQ3 earnings guidance excludes approximately 7c per diluted share of projected intangible asset amortization expense."
07:04 EDTBAXBaxter narrows FY14 adjusted EPS view to $5.10-$5.20, consensus $5.15
Subscribe for More Information
07:02 EDTBAXBaxter reports Q2 adjusted EPS $1.26, consensus $1.22
Reports Q2 revenue $4.26B, consensus $4.12B.
07:01 EDTBAXBaxter confirms FY14 outlook
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use